Definition and management of radioactive iodine-refractory differentiated thyroid cancer

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 5, 2014, Pages 356-358

  Schlumberger, Martin ^a   Brose, Marcia ^b   Elisei, Rosella ^c   Leboulleux, Sophie ^a   Luster, Markus ^d   Pitoia, Fabian ^e   Pacini, Furio ^f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^f UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN; RADIOACTIVE IODINE;

CANCER CHEMOTHERAPY; CANCER GROWTH; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIATED THYROID CANCER; DISEASE SURVEILLANCE; DISTANT METASTASIS; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG UPTAKE; HUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; TUMOR VOLUME; ALGORITHM; THYROID NEOPLASMS; ABLATION THERAPY; EXTERNAL BEAM RADIOTHERAPY; METASTASIS; PRACTICE GUIDELINE; RADIOACTIVITY; THERMOABLATION; THYROID SURGERY;

ALGORITHMS; HUMANS; IODINE RADIOISOTOPES; THYROID NEOPLASMS;

EID: 84899688629     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70215-8     Document Type: Note

References (10)

1. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006, 91:2892-2899.
2. Sabra MM, Grewal RK, Tala H, Larson SM, Tuttle RM Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. Thyroid 2012, 22:877-883.
3. Sgouros G, Kolbert KS, Sheikh A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004, 45:1366-1372.
4. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006, 91:498-505.
5. Leboulleux S, El Bez I, Borget I, et al. Post-radioiodine treatment whole body scan in the era of Fluorodesoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid 2012, 22:832-838.
6. Vaisman F, Tala H, Grewal R, Tuttle RM In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid 2011, 21:1317-1322.
7. Deandreis D, Al Ghuzlan A, Leboulleux S, et al. Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptake) patterns of metastatic thyroid cancer correlate with patient outcome?. Endocr Relat Cancer 2011, 18:159-169.
8. Rubino C, De Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003, 89:1638-1644.
9. Xing MM, Haugen B, Schlumberger M Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013, 381:1058-1069.
10. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 2008, 113:48-56.